분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2007-06-04 18:47:33 , Hit : 4465
 Genetically Modified Stem Cells May Have Therapeutic Application to X-SCID

A study demonstrating therapeutic utilization of human stem cells, including potential application to X-linked Severe Combined Immunodeficiency (XSCID or “Bubble-Boy” disease) was presented today at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

X-linked Severe Combined Immunodeficiency (XSCID) is a rare genetic disease caused by defects in an essential immune hormone receptor called the common gamma chain (γc), found on the surface of lymphocytes and other immune blood cells. Patients with XCID have immune cells that lack this receptor and both fail to develop properly, as well as do not function normally to protect patients against infections.

A team of scientists led by Dr. Luigi Naldini from the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan and Sangamo BioSciences Inc., Richmond, CA, are developing a novel approach to genetically modify embryonic and tissue stem cells for therapeutic use. This approach can potentially be applied to many diseases, including X-SCID.

Using technology developed by Sangamo, the scientists showed gene correction or precise addition of a gene in human stem cells at unprecedented levels.

“This is a significant advance for the potential therapeutic use of stem cells,” says Dr. Angelo Lombardo, lead author of the study. “Stem cells are the body’s natural resource for regeneration and repair and the ability to efficiently insert a therapeutic gene in a predetermined location or to correct a mutated gene in a patient’s stem cells may enable us to provide a long term solution for many genetic diseases. The powerful combination of Sangamo’s ZFN™ technology and our highly efficient viral delivery platform was the key factor for obtaining unprecedented gene modification efficiency in these therapeutically important cells”.

Using this approach, an inherited mutation in a gene can be directly corrected or modified in a cell or a new copy of a gene can be added into the genome at a specific and predetermined site. This is a significant advance over traditional approaches that rely on the random insertion of a new copy of a gene to cells to restore the missing function of an inherited mutant gene. In fact, despite the successful outcome of gene therapy reported in many SCID patients, random insertion of genes into the cellular genome may in some circumstances lead to serious adverse effects due to altered expression of the therapeutic gene or its neighboring genes at the insertion site.

In contrast, Dr. Naldini’s study demonstrates that ZFN-mediated gene editing can be used to correct mutations in the IL-2R gamma gene, the defective gene in X-linked SCID, and to add a therapeutic gene to a pre-determined ‘safe-harbor’ site in the genome of both human hematopoietic progenitors and human ES cells with high efficiency. This ‘safe-harbor site’ was selected by the investigators for its capacity to allow efficient expression of the therapeutic gene and to tolerate an insertion event without adverse effects.

ZFN-mediated gene editing overcomes some major limitations of standard gene therapy approaches and potentially provides a unique means to treat disease with HSCs and ES cells in a safe and effective manner.

The scientists used novel designer proteins, named zinc finger DNA-binding protein nucleases (ZFN), that were developed at Sangamo BioSciences. ZFN can be engineered to specifically cut DNA at a chosen site.

Dr. Naldini’s team exploited the high infectious capacity of lentiviral vectors derived from HIV to express ZFN and provide the template DNA for gene correction in target cells. When they introduced ZFN into target cells with an appropriately designed donor DNA molecule that encodes the correct gene sequence, the DNA break was repaired in a natural process by the cell’s DNA-repair machinery leading to correction of the mutation or the preci







1127   마이크로 RNA가 면역계에 미치는 영향  이성욱 2007/04/30 4765
1126   DNA 수복의 오류가 헌팅턴병을 초래  관리자 2007/05/01 4255
1125   알츠하이머에 효과적인 신규 물질  관리자 2007/05/01 4005
1124   죽음에 관한 기존 학설 깨졌다<뉴스위크>  관리자 2007/05/03 3699
1123   췌장암 진단과 치료에 도움을 주는 microRNA 연구  이성욱 2007/05/03 5103
1122   류마티스 관절염에 효과를 보인 녹차성분 EGCG  이성욱 2007/05/03 5233
1121   유방암 치료에 획기적인 병용치료법  이성욱 2007/05/10 5416
1120   마이크로RNA 유전자 발현 억제 기전 규명  이성욱 2007/05/18 4762
1119   p53: 양면의 날을 가진 검(劍)  이성욱 2007/05/18 4504
1118   New gene therapy targets cholesterol  이성욱 2007/05/22 3892
1117   인간과 헤르페스바이러스는 공생관계?  이성욱 2007/05/23 7156
1116   방사선을 먹는 진균 발견  이성욱 2007/05/25 6859
1115   1형 당뇨병 백신, 동물 실험에서 효과  이성욱 2007/05/28 4678
1114   기억과 학습에도 영향을 주는 알츠하이머 관련 유전자  관리자 2007/05/31 4031
1113   마리화나 중독을 차단하는 식물 추출물  관리자 2007/05/31 4207
1112   나노입자를 이용한 선택적 전립선 암 치료 연구  관리자 2007/06/01 4203
1111   제대혈 줄기세포에서 인슐린을 생산  관리자 2007/06/01 3767
1110   Gene therapy 'hope' on impotence  이성욱 2007/06/04 4991
  Genetically Modified Stem Cells May Have Therapeutic Application to X-SCID  이성욱 2007/06/04 4465
1108   장기기억을 향상시키는 항암제  관리자 2007/06/08 4498

[1][2][3][4][5][6][7] 8 [9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN